Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 14-Nov-24 2:44 PM View:  | Guyer Charles Greg EVP, Chief Technical Officer | BioMarin Pharmaceutical Inc. (BMRN) | 12-Nov-24 | Sale | 5,278 | $66.37 | $350,324.00 | (7%) 74.19K to 68.91K | |
| 14-Nov-24 2:44 PM View: | Guyer Charles Greg EVP, Chief Technical Officer | BioMarin Pharmaceutical Inc. (BMRN) | 31-Oct-24 | Grant | 55 | $56.01 | $3,080.39 | < 1% 74.13K to 74.19K | |
| 01-Oct-24 4:51 PM View: | Friberg Gregory R EVP, Chief R&D Officer | BioMarin Pharmaceutical Inc. (BMRN) | 30-Sep-24 | Grant | 29,060 | -- | -- | 100% 0 to 29.06K | |
| 17-Sep-24 5:54 PM View: | Fuchs Henry J President, Worldwide R&D | BioMarin Pharmaceutical Inc. (BMRN) | 13-Sep-24 | Payment of Exercise | 12,098 | $84.90 | $1,027,120.00 | (6%) 197.17K to 185.07K | |
| 15-Aug-24 3:57 PM View: | Burkhart Erin GVP, Chief Accounting Officer | BioMarin Pharmaceutical Inc. (BMRN) | 13-Aug-24 | Market Sale | 714 | $90.00 | $64,260.00 | (5%) 15.16K to 14.45K | 6% |
| 04-Jun-24 7:29 PM View: | Heron Elaine J Director | BioMarin Pharmaceutical Inc. (BMRN) | 03-Jun-24 | Payment of Exercise | 4,168 | $76.41 | $318,477.00 | (4%) 101.89K to 97.72K | |
| 04-Jun-24 7:28 PM View: | Meier Richard A Director | BioMarin Pharmaceutical Inc. (BMRN) | 03-Jun-24 | Option Exercise | 6,600 | $63.10 | $416,460.00 | 6% 119.63K to 126.23K | |
| 04-Jun-24 7:29 PM View: | Heron Elaine J Director | BioMarin Pharmaceutical Inc. (BMRN) | 03-Jun-24 | Option Exercise | 5,047 | $63.10 | $318,466.00 | 5% 96.84K to 101.89K | |
| 04-Jun-24 7:28 PM View: | Meier Richard A Director | BioMarin Pharmaceutical Inc. (BMRN) | 03-Jun-24 | Payment of Exercise | 5,451 | $76.41 | $416,511.00 | (4%) 126.23K to 120.78K | |
| 31-May-24 6:28 PM View: | Mueller Brian EVP, Chief Financial Officer | BioMarin Pharmaceutical Inc. (BMRN) | 30-May-24 | Option Sale | 5,000 | $75.19 | $375,950.00 | (6%) 77.16K to 72.16K | |
| 31-May-24 6:28 PM View: | Mueller Brian EVP, Chief Financial Officer | BioMarin Pharmaceutical Inc. (BMRN) | 30-May-24 | Option Exercise | 5,000 | $63.10 | $315,500.00 | 7% 72.16K to 77.16K | |
| 30-May-24 6:18 PM View: | Davis George Eric EVP, Chief Legal Officer | BioMarin Pharmaceutical Inc. (BMRN) | 28-May-24 | Option Sale | 40,850 | $74.51 | $3,043,800.00 | (42%) 97.01K to 56.16K | |
| 30-May-24 6:18 PM View: | Davis George Eric EVP, Chief Legal Officer | BioMarin Pharmaceutical Inc. (BMRN) | 28-May-24 | Option Exercise | 40,850 | $63.10 | $2,577,640.00 | 73% 56.16K to 97.01K | |
| 23-May-24 5:33 PM View: | Hombach Robert J. Director | BioMarin Pharmaceutical Inc. (BMRN) | 21-May-24 | Grant | 4,720 | -- | -- | 15% 30.5K to 35.22K | |
| 23-May-24 5:30 PM View: | Ho Maykin Director | BioMarin Pharmaceutical Inc. (BMRN) | 21-May-24 | Grant | 4,720 | -- | -- | 28% 16.64K to 21.36K | |
| 23-May-24 5:20 PM View: | Dere Willard H Director | BioMarin Pharmaceutical Inc. (BMRN) | 21-May-24 | Grant | 4,720 | -- | -- | 17% 27.58K to 32.3K | |
| 23-May-24 5:36 PM View: | Pyott David E I Director | BioMarin Pharmaceutical Inc. (BMRN) | 21-May-24 | Grant | 4,720 | -- | -- | 10% 45.03K to 49.75K | |
| 23-May-24 5:08 PM View: | Bodem Barbara W. Director | BioMarin Pharmaceutical Inc. (BMRN) | 21-May-24 | Grant | 4,720 | -- | -- | 217% 2.18K to 6.9K | |
| 23-May-24 5:34 PM View: | Meier Richard A Director | BioMarin Pharmaceutical Inc. (BMRN) | 21-May-24 | Grant | 7,080 | -- | -- | 6% 112.55K to 119.63K | |
| 23-May-24 5:23 PM View: | Enyedy Mark J Director | BioMarin Pharmaceutical Inc. (BMRN) | 21-May-24 | Grant | 4,720 | -- | -- | 217% 2.18K to 6.9K | |
| 23-May-24 5:06 PM View: | Anderson Elizabeth M Director | BioMarin Pharmaceutical Inc. (BMRN) | 21-May-24 | Grant | 4,720 | -- | -- | 20% 23.08K to 27.8K | |
| 23-May-24 5:26 PM View: | Heron Elaine J Director | BioMarin Pharmaceutical Inc. (BMRN) | 21-May-24 | Grant | 4,720 | -- | -- | 5% 92.12K to 96.84K | |
| 23-May-24 5:14 PM View: | Countouriotis Athena Director | BioMarin Pharmaceutical Inc. (BMRN) | 21-May-24 | Grant | 4,720 | -- | -- | 217% 2.18K to 6.9K | |
| 21-May-24 4:09 PM View: | Bienaime Jean Jacques Director | BioMarin Pharmaceutical Inc. (BMRN) | 20-May-24 | Payment of Exercise | 1,202 | $77.05 | $92,614.10 | (< 1%) 722.53K to 721.33K | (10%) |
| 22-May-24 4:36 PM View: | Hubbard Cristin EVP, Chief Commercial Officer | BioMarin Pharmaceutical Inc. (BMRN) | 20-May-24 | Grant | 19,390 | -- | -- | 100% 0 to 19.39K | |
| 20-May-24 5:20 PM View: | Burkhart Erin GVP, Chief Accounting Officer | BioMarin Pharmaceutical Inc. (BMRN) | 17-May-24 | Payment of Exercise | 993 | $76.97 | $76,431.20 | (6%) 16.16K to 15.16K | (10%) |
| 13-May-24 3:57 PM View: | Bienaime Jean Jacques Director | BioMarin Pharmaceutical Inc. (BMRN) | 10-May-24 | Option Exercise | 20,000 | $63.10 | $1,262,000.00 | 3% 722.53K to 742.53K | |
| 13-May-24 3:57 PM View: | Bienaime Jean Jacques Director | BioMarin Pharmaceutical Inc. (BMRN) | 10-May-24 | Option Sale | 20,000 | $81.14 | $1,622,800.00 | (3%) 742.53K to 722.53K | |
| 13-May-24 3:57 PM View: | Bienaime Jean Jacques Director | BioMarin Pharmaceutical Inc. (BMRN) | 09-May-24 | Option Exercise | 20,000 | $63.10 | $1,262,000.00 | 3% 722.53K to 742.53K | |
| 13-May-24 3:57 PM View: | Bienaime Jean Jacques Director | BioMarin Pharmaceutical Inc. (BMRN) | 09-May-24 | Option Sale | 20,000 | $81.62 | $1,632,400.00 | (3%) 742.53K to 722.53K | |
| 07-May-24 5:58 PM View: | Guyer Charles Greg EVP, Chief Technical Officer | BioMarin Pharmaceutical Inc. (BMRN) | 03-May-24 | Payment of Exercise | 4,440 | $82.44 | $366,034.00 | (6%) 78.57K to 74.13K | |
| 06-May-24 4:45 PM View: | Davis George Eric EVP, Chief Legal Officer | BioMarin Pharmaceutical Inc. (BMRN) | 02-May-24 | Option Exercise | 1,850 | $63.10 | $116,735.00 | 3% 56.16K to 58.01K | |
| 06-May-24 4:45 PM View: | Davis George Eric EVP, Chief Legal Officer | BioMarin Pharmaceutical Inc. (BMRN) | 02-May-24 | Option Sale | 1,850 | $85.01 | $157,268.00 | (3%) 58.01K to 56.16K | |
| 06-May-24 4:40 PM View: | Ajer Jeffrey Robert EVP, Chief Commercial Officer | BioMarin Pharmaceutical Inc. (BMRN) | 02-May-24 | Sale | 5,000 | $82.91 | $414,550.00 | (7%) 71.77K to 66.77K | |
| 17-Sep-24 5:54 PM View: | Fuchs Henry J President, Worldwide R&D | BioMarin Pharmaceutical Inc. (BMRN) | 30-Apr-24 | Grant | 300 | $68.65 | $20,593.80 | < 1% 196.87K to 197.17K | |
| 07-May-24 5:58 PM View: | Guyer Charles Greg EVP, Chief Technical Officer | BioMarin Pharmaceutical Inc. (BMRN) | 30-Apr-24 | Grant | 245 | $68.65 | $16,818.30 | < 1% 78.33K to 78.57K | |
| 31-May-24 6:28 PM View: | Mueller Brian EVP, Chief Financial Officer | BioMarin Pharmaceutical Inc. (BMRN) | 30-Apr-24 | Grant | 300 | $68.65 | $20,593.80 | < 1% 71.86K to 72.16K | |
| 06-May-24 4:40 PM View: | Ajer Jeffrey Robert EVP, Chief Commercial Officer | BioMarin Pharmaceutical Inc. (BMRN) | 30-Apr-24 | Grant | 300 | $68.65 | $20,593.80 | < 1% 71.47K to 71.77K | |
| 06-May-24 4:45 PM View: | Davis George Eric EVP, Chief Legal Officer | BioMarin Pharmaceutical Inc. (BMRN) | 30-Apr-24 | Grant | 301 | $68.65 | $20,662.40 | < 1% 55.86K to 56.16K | |
| 15-Apr-24 4:21 PM View: | Bienaime Jean Jacques Director | BioMarin Pharmaceutical Inc. (BMRN) | 12-Apr-24 | Option Exercise | 20,000 | $63.10 | $1,262,000.00 | 3% 722.53K to 742.53K | |
| 15-Apr-24 4:21 PM View: | Bienaime Jean Jacques Director | BioMarin Pharmaceutical Inc. (BMRN) | 12-Apr-24 | Option Sale | 20,000 | $91.26 | $1,825,200.00 | (3%) 742.53K to 722.53K | |
| 15-Apr-24 4:21 PM View: | Bienaime Jean Jacques Director | BioMarin Pharmaceutical Inc. (BMRN) | 11-Apr-24 | Option Exercise | 20,000 | $63.10 | $1,262,000.00 | 3% 722.53K to 742.53K | |
| 15-Apr-24 4:21 PM View: | Bienaime Jean Jacques Director | BioMarin Pharmaceutical Inc. (BMRN) | 11-Apr-24 | Option Sale | 20,000 | $90.99 | $1,819,800.00 | (3%) 742.53K to 722.53K | |
| 12-Apr-24 3:07 PM View: | Burkhart Erin GVP, Chief Accounting Officer | BioMarin Pharmaceutical Inc. (BMRN) | 10-Apr-24 | Market Sale | 2,286 | $90.00 | $205,740.00 | (12%) 18.44K to 16.16K | 6% |
| 01-Apr-24 4:54 PM View: | Davis George Eric EVP, Chief Legal Officer | BioMarin Pharmaceutical Inc. (BMRN) | 28-Mar-24 | Market Sale | 24,602 | $88.34 | $2,173,340.00 | (31%) 80.46K to 55.86K | 4% |
| 20-Mar-24 5:13 PM View: | Slamon Dennis Director | BioMarin Pharmaceutical Inc. (BMRN) | 18-Mar-24 | Option Exercise | 10,000 | $79.70 | $797,000.00 | 32% 30.81K to 40.81K | 6% |
| 20-Mar-24 5:13 PM View: | Slamon Dennis Director | BioMarin Pharmaceutical Inc. (BMRN) | 18-Mar-24 | Payment of Exercise | 9,510 | $83.81 | $797,033.00 | (23%) 40.81K to 31.3K | (< 1%) |
| 19-Mar-24 8:55 PM View: | Burkhart Erin GVP, Chief Accounting Officer | BioMarin Pharmaceutical Inc. (BMRN) | 18-Mar-24 | Payment of Exercise | 372 | $83.87 | $31,199.60 | (2%) 18.81K to 18.44K | |
| 19-Mar-24 8:40 PM View: | Bienaime Jean Jacques Director | BioMarin Pharmaceutical Inc. (BMRN) | 15-Mar-24 | Payment of Exercise | 85,209 | $83.87 | $7,146,480.00 | (11%) 807.74K to 722.53K | (< 1%) |
| 19-Mar-24 8:46 PM View: | Fuchs Henry J President, Worldwide R&D | BioMarin Pharmaceutical Inc. (BMRN) | 15-Mar-24 | Grant | 18,240 | -- | -- | 9% 212.12K to 230.36K |
